XDX Named 2006 Technology Pioneer by World Economic Forum
News Jan 06, 2006
Technology Pioneers are companies that have been identified as developing and applying highly transformational and innovative technologies in the areas of energy, biotechnology and health, and information technology.
This year’s class of companies has been selected not only because of the cutting-edge work undertaken by the organizations but also because their work has potential long-term impact on business and society.
"The creative innovations produced by our Technology Pioneers hold the promise of significantly affecting the way business and society operate," said Peter Torreele, managing director of the World Economic Forum.
"As a global knowledge hub, we see the Technology Pioneer community as key contributors to this dialogue and to the mission of the World Economic Forum."
One of this year's Technology Pioneers is XDx, a molecular diagnostics company that is setting the stage for a new era in personalized medicine as one of the first companies to develop and commercialize practical applications built on insights from the Human Genome Project.
The company’s first product is AlloMap™ molecular expression testing, a proprietary method for non-invasively monitoring the immune system by measuring gene expression in a patients’ blood.
Currently heart transplant recipients undergo a series of biopsies, an invasive and subjective method that detects rejection only after tissue has been damaged and carries significant risk of adverse effects.
Now from a simple blood sample collected from the patient, AlloMap testing can extract, analyze and translate complex gene information into a single score that provides objective information to help physicians better manage and treat patients.
AlloMap testing has been clinically validated and is being used at top transplant centers across the United States.
"We are honoured to have been selected as a Technology Pioneer for 2006 as a result of our advancements in molecular diagnostics that are improving patient’s lives," said Pierre Cassigneul, CEO, XDx.
"This recognition further validates what transplant centers worldwide have seen. We hope this added recognition will provide XDx with a higher level of visibility and credibility that helps us reach our goals for success."
As genome editing technologies advance toward clinical therapies, they are raising hopes of a completely new way to treat disease. However, challenges need to be addressed before potential treatments can be widely used in patients. To tackle these challenges, the National Institutes of Health has launched the Somatic Cell Genome Editing program, which has awarded multiple grants including more than $3.6 million to assess the safety of genome editing in human cells and tissues.